Key result
Elevated fibrinogen is linked to ~8-fold higher odds of complicated lesions in NSTEMI.
Why the study?
The study was conducted to evaluate associations between systemic inflammation markers and the severity of infarct-related artery involvement on coronary angiography in patients with NSTEMI.
Do elevated levels of systemic inflammation markers associate with complicated infarct-related artery lesions in patients with NSTEMI?
Observational (n=236)
No
Do elevated levels of systemic inflammation markers associate with complicated infarct-related artery lesions in patients with NSTEMI?
Systemic inflammation markers, particularly fibrinogen and hsCRP, can help identify NSTEMI patients who are at higher risk of possessing complicated coronary atherosclerotic lesions.
May aid NSTEMI lesion risk stratification by inflammation markers; leaves open causal role and need for prospective validation.
Aim. To study the associations between the level of systemic inflammation markers in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and the severity of infarct-related artery (IRA) involvement according to coronary angiography. Material and methods. The data of 236 patients hospitalized with a diagnosis of NSTEMI in the regional vascular center in Odintsovo from April 2021 to February 2023 were analyzed. All patients underwent examinations in accordance with clinical guidelines. Based on laboratory tests, the level of following inflammatory markers was assessed: leukocytes, high-sensitivity C-reactive protein (hsCRP), fibrinogen. During coronary angiography, the IRA involvement was assessed according to American College of Cardiology/American Heart Association classification. The relationship of inflammatory markers with complicated involvement was assessed in a binary logistic regression model. Results. Depending on the severity of the IRA involvement, the patients were divided into 2 following groups: group 1 included 166 patients with complicated IRA involvement (type B-C), group 2 — 70 patients without complicated IRA involvement (type A). Patients in both groups were comparable in terms of troponin I levels upon admission (p>0,05). Inflammatory markers were significantly higher in group 1 (p≲0,05). Fatal outcome was observed in 4,2% (n=7) of cases in group 1 and in 2,9% (n=2) in group 2 (p=0,62). Levels of hsCRP (odds ratio (OR) 1,19) and fibrinogen (OR 7,96) were associated with the probability of type B-C IRA lesion (p<0,001). Conclusion. Patients with NSTEMI and complicated IRA lesions are characterized by elevated levels of systemic inflammation markers. Higher levels of hsCRP and fibrinogen were significantly associated with type B and C lesions.
No takes yet. Share an insight, caveat, or question.
Strelkova et al. (2025) conducted an observational in non-ST-segment elevation myocardial infarction (NSTEMI) (n=236). Elevated levels of systemic inflammation markers (fibrinogen, hsCRP) vs. Lower or normal levels of systemic inflammation markers was evaluated on Probability of complicated infarct-related artery involvement (ACC/AHA type B-C) (OR 7.96, 95% CI 4.33-14.62, p=<0.001). Higher levels of fibrinogen (OR 7.96) and hsCRP (OR 1.19) were significantly associated with complicated type B and C infarct-related artery lesions in NSTEMI patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: